Guidance for the prevention and treatment of cancer-associated venous thromboembolism

Journal of Thrombosis and Thrombolysis

Volumn 41, Issue 1, 2016, Pages 81-91

  Khorana, Alok A ^a   Carrier, Marc ^b   Garcia, David A ^c   Lee, Agnes Y Y ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cancer; Direct oral anticoagulants (DOAC); New oral anticoagulants (NOAC); Prevention; Risk factors; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; CANCER PATIENT; EMBOLISM PREVENTION; EVIDENCE BASED PRACTICE; HUMAN; META ANALYSIS (TOPIC); PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; NEOPLASMS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 84954432425     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1313-4     Document Type: Article

References (46)

1. Khorana AA, McCrae KR (2014) Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res 133(Suppl 2):S35–S38
2. Khorana AA, O’Connell C, Agnelli G, Liebman HA, Lee AY (2012) Incidental venous thromboembolism in oncology patients. J Thromb Haemost 10(12):2602–2604
3. Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484–3488
4. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632–634
5. Khorana AA, Dalal MR, Lin J, Connolly GC (2013) Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res 5:101–108
6. Mandala M, Falanga A, Roila F (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 22(Suppl 6):vi85–92
7. Lyman GH, Khorana AA, Kuderer NM et al (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(17):2189–2204
8. Streiff MB, Bockenstedt PL, Cataland SR et al (2013) Venous thromboembolic disease. J Natl Compr Canc Netw 11(11):1402–1429
9. Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA (2008) Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med 149(5):323–333
10. White RH, Chew HK, Zhou H et al (2005) Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 165(15):1782–1787
11. Iodice S, Gandini S, Lohr M, Lowenfels AB, Maisonneuve P (2008) Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis. J Thromb Haemost 6(5):781–788
12. Prandoni P, Casiglia E, Piccioli A et al (2010) The risk of cancer in patients with venous thromboembolism does not exceed that expected in the general population after the first 6 months. J Thromb Haemost 8(5):1126–1127
13. Van Doormaal FF, Terpstra W, Van Der Griend R et al (2011) Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J Thromb Haemost 9(1):79–84
14. Piccioli A, Lensing AW, Prins MH et al (2004) Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2(6):884–889
15. Din M, Otten HM, Piccioli A et al (2005) Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost 3(11):2391–2396
16. Langford N, Stansby G, Avital L (2012) The management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE Guideline CG144. Acute Med 11(3):138–142
17. Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9(7):e1001275
18. Scappaticci FA, Fehrenbacher L, Cartwright T et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91(3):173–180
19. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28(13):2280–2285
20. Cavo M, Zamagni E, Cellini C et al (2002) Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100(6):2272–2273
21. Petrelli F, Cabiddu M, Borgonovo K, Barni S (2012) Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 23(7):1672–1679
22. Pabinger I, Thaler J, Ay C (2013) Biomarkers for prediction of venous thromboembolism in cancer. Blood 122(12):2011–2018
23. Agnelli G, Gussoni G, Bianchini C et al (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10(10):943–949
24. Agnelli G, George DJ, Kakkar AK et al (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366(7):601–609
25. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907
26. Ay C, Dunkler D, Marosi C et al (2010) Prediction of venous thromboembolism in cancer patients. Blood 116(24):5377–5382
27. Di Nisio M, Porreca E, Ferrante N, Otten H-M, Cuccurullo F, Rutjes AWS (2012) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2:CD008500. doi:10.1002/14651858.CD008500.pub2
28. Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7(3):291–292
29. George DJ AG, Fisher W, AK K, Lassen MR, et al. (2011) Poster presentation: venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. https://ash.confex.com/ash/2011/webprogram/Paper39639.html. Accessed 27 April 27 2015
30. Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI (2014) Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med 127(1):82–86 e81
31. Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153
32. Akl EA, Barba M, Rohilla S et al (2008) Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res 27(1):21
33. Lee AY, Bauersachs R, Janas MS et al (2013) CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 13:284
34. Lee AYY, Kamphuisen PW, Meyer G et al (2015) Tinzaparin vs Warfarin for treatment of Acute Venous Thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314(7):677–686
35. Agency EM. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed 12 January 12 2015
36. Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY (2014) Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 134(6):1214–1219
37. Connolly GC, Menapace L, Safadjou S, Francis CW, Khorana AA (2013) Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients. Clin Lung Cancer 14(6):713–718. doi:10.1016/j.cllc.2013.06.003
38. Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA (2011) Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 106(2):371–378
39. Chaturvedi S, Sidana S, Elson P, Khorana AA, McCrae KR (2014) Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PLoS One 9(8):e94048
40. den Exter PL, Hooijer J, Dekkers OM, Huisman MV (2011) Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 29(17):2405–2409
41. Carrier M, Righini M, Le Gal G (2012) Symptomatic subsegmental pulmonary embolism: what is the next step? J Thromb Haemost 10(8):1486–1490
42. Singh R, Sousou T, Mohile S, Khorana AA (2010) High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost 8(8):1879–1881
43. Ageno W, Squizzato A, Togna A et al (2012) Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study. J Thromb Haemost 10(1):158–160
44. Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY (2009) Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 7(5):760–765
45. Carrier M, Khorana AA, Zwicker J et al (2013) Management of challenging cases of patients with cancer associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 11(9):1760–1765
46. Matsuo K, Carter CM, Ahn EH et al (2013) Inferior vena cava filter placement and risk of hematogenous distant metastasis in ovarian cancer. Am J Clin Oncol 36(4):362–367